Study of the Medullary Microenvironment in Acute Childhood Leukemia

Status Recruiting

Clinical Trial Summary

Acute leukemia (AL) is the most common cancer in children. Despite the optimization of chemotherapy treatments and the development of supportive care, a certain number of LAs relapse and/or progress to death of the child. It therefore seems essential to try to better understand the physiopathology and the mechanisms of resistance to treatment of these diseases.

Clinical Trial Description

Acute leukemia (AL) is the most common cancer in children. Despite the optimization of chemotherapy treatments and the development of supportive care, a certain number of AL's relapse and/or progress to death of the child. It therefore seems essential to try to better understand the physiopathology and the mechanisms of resistance to treatment of these diseases. The study of the microenvironment appears in this context as a promising avenue. The bone marrow microenvironment is composed of an extracellular matrix and cells, in particular mesenchymal stromal stem cells (MSC's). In adult acute leukemia, it has been clearly demonstrated that these microenvironment cells are reprogrammed by leukemia cells to allow the development and proliferation of the latter. Links have also been demonstrated in acute leukemia between the cells of the microenvironment and resistance to chemotherapy. In a certain number of cases, the support of the microenvironment for the development of leukemia or resistance to chemotherapy involves modulation of the energy metabolism of leukemia cells. This notably involves interactions between leukemic cells and MSCs and re-programming of the energy metabolism of the latter. To date, there are only very few studies concerning the role of the microenvironment in acute childhood leukemia and none to date has specifically studied the energy metabolism (oxidative phosphorylation and glycolysis) of MSCs. ;

Study Design

Related Conditions & MeSH terms

Acute Lymphoid Leukemia
Acute Myeloid Leukemia in Children
Leukemia
Leukemia, Lymphoid
Precursor Cell Lymphoblastic Leukemia-Lymphoma

Clinical Trial Details

NCT number	NCT05792007
Study type	Interventional
Source	University Hospital, Tours
Contact	Olivier HERAULT, MD-PhD
Phone	+33(0)234378902
Email	olivier.herault@univ-tours.fr
Status	Recruiting
Phase	N/A
Start date	October 26, 2023
Completion date	October 24, 2028

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05959720` - Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil
Recruiting	`NCT02933333` - G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor	Phase 4
Completed	`NCT02953730` - The Study on the Pharmacokinetics of PEG-rhG-CSF in Children and Adolescents	Phase 4
Completed	`NCT02767388` - Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery
Recruiting	`NCT03610438` - Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia	Phase 2
Completed	`NCT02294552` - Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT	Phase 2
Completed	`NCT01461538` - Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies	Phase 2
Recruiting	`NCT04167683` - Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant
Recruiting	`NCT05150561` - Muscle Dysfunction in Patients With Haematological Diseases
Active, not recruiting	`NCT04669210` - PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT	Phase 2
Active, not recruiting	`NCT04013685` - Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies	Phase 1
Recruiting	`NCT02345915` - Evaluation of Adverse Long-term Effects in Young Adult Survivors of Acute Leukemia	N/A
Completed	`NCT01720264` - Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant	Phase 2
Not yet recruiting	`NCT02413021` - The Effect of Deferasirox on Response Rate of Acute Leukemia Patients Not Treated by Standard Chemotherapy Regimens	Phase 1
Not yet recruiting	`NCT06427330` - Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia	Phase 2
Active, not recruiting	`NCT04778579` - Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to Therapy	Phase 2
Recruiting	`NCT03448393` - CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies	Phase 1
Completed	`NCT03833180` - A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)	Phase 1
Active, not recruiting	`NCT03367299` - Sequential Chemotherapy and Blinatumomab to Improve MRD Response and Survival in Acute Lymphoblastic Leukemia	Phase 2
Terminated	`NCT02435550` - iCare for Cancer Patients	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Study of the Medullary Microenvironment in Acute Childhood Leukemia — MILA

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms